Effect of Compound Danshen Dripping Pill combined with polyene phosphatidyl choline in treatment of nonalcoholic fatty liver disease / 药物评价研究

ABSTRACT

Objective To investigate the clinical effect of Compound Danshen Dripping Pill (CDCP) combined with polyene phosphatidyl choline in the treatment of nonalcoholic fatty liver disease.Methods Patients with nonalcoholic fatty liver disease (116 cases) treated in Xi'an Medical University Affiliated Baoji Hospital from January 2012 to December 2015 were selected and divided into two groups randomly.Control group was treated with CDDP,and observation group was treated with CDDP combined with polyene phosphatidyl choline,the two groups were treated for 3 months.The clinical efficiency of two groups was compared.The following indicators were detected before and after treatment respectively,such as liver function indicatorsaspartate aminotransferase (AST),alanine aminotransferase (ALT),γ-glutamyltransferase (γ-GT) and total bile acid (TBIL);blood lipid indicatorstotal cholesterol (TC),triacylglycerol (TG);and liver triglyceride fibrosis indicatorslaminin (LN),hyaluronic acid (HA),procollagen Ⅲ (PC Ⅲ),and type Ⅳ collagen (Ⅳ-C),and carried on the upper abdomen CT plain scan,the liver/spleen CT ratio were calculated.Results After treatment,the effective rate of the observation group was 91.4％ (53/58),significantly higher than that of the control group 72.4％ (42/58) (P ＜ 0.05).After treatment,the levels of AST,ALT,γ-GT,TBIL,TC and TG in two groups were decreased significantly compared with the same group before treatment and lower in the observation group (P ＜ 0.05),and liver/spleen CT ratio was increased significantly and higher in the observation group (P ＜ 0.05).After treatment,the levels of LN,PC Ⅲ,Ⅳ-C and HA in two groups were decreased significantly compared with the same group before treatment and lower in the observation group (P ＜ 0.05).Conclusion CDDP combined with polyene phosphatidyl choline can significantly improve the liver function and liver fibrosis in patients with nonalcoholic fatty liver disease,and lower blood lipid,which has high clinical value.